Lv31
320 积分 2021-03-11 加入
Podocytopathies
1小时前
已完结
Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis
1小时前
已完结
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
1个月前
已完结
A tale of two antibodies: obinutuzumab versus rituximab
1个月前
已完结
Targeting B Cells and Plasma Cells in Glomerular Disease
2个月前
已完结
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
2个月前
已完结
Obinutuzumab is effective for the treatment of frequently-relapsing/steroid-dependent minimal change disease in adults
3个月前
已完结
B cell dysregulation and depletion therapy in primary membranous nephropathy: Prospects and potential challenges
3个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
3个月前
已完结
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy
3个月前
已完结
皖公网安备34019202002308
